Last10K.com

Orchard Therapeutics Plc (ORTX) SEC Filing 6-K Foreign Issuer report for the period ending Monday, September 30, 2019

Orchard Therapeutics Plc

HISTORY TOOLS
CIK: 1748907 Ticker: ORTX

View differences made from one to another to evaluate Orchard Therapeutics Plc's financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 6-K Foreign Issuer Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Orchard Therapeutics Plc.

Continue

Assess how Orchard Therapeutics Plc's management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Orchard Therapeutics Plc's Definitive Proxy Statement (Form DEF 14A) filed after their 2019 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors

Continue

Tools

Material Contracts, Statements, Certifications & more

Orchard Therapeutics Plc provided additional information to their SEC Filing as exhibits

Exhibit 99.1: Additional Exhibits
Ticker: ORTX
CIK: 1748907
Form Type: 6-K Foreign Issuer Report
Accession Number: 0001564590-19-035906
Submitted to the SEC: Mon Sep 30 2019 4:00:22 PM EST
Accepted by the SEC: Mon Sep 30 2019
Period: Monday, September 30, 2019
Industry: Biological Products No Disgnostic Substances

External Resources:
Stock Quote
Social Media

Bookmark the Permalink:
https://last10k.com/sec-filings/ortx/0001564590-19-035906.htm